105results about How to "Reduce bacterial load" patented technology

The present invention discloses fusion proteins of the immunodominant antigens ESAT-6 and Ag85B from Mycobacterium tuberculosis or homologues thereof, and a tuberculosis vaccine based on the fusion proteins, which vaccine induces efficient immunological memory.

Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).

Ventilator associated pneumonia (VAP) may be prevented in a patient, or its occurrence reduced in a population of patients, by using an anti-VAP device or an anti-VAP material. By reducing the problem of bacterial-containing secretions that otherwise build up in the airway of the intubated patient, VAP can be prevented from occurring in intubated patients, such as patients intubated with an endotracheal tube (ETT) or a nasogastric tube.

The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.

The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides.

The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and / or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

A method for performing a surgical or medical procedure on a portion of a patient's body within a surgical environment enclosure may involve preparing the surgical environment enclosure for performing the procedure, advancing the portion of the patient's body into the surgical environment enclosure through a first port on the enclosure, and performing the surgical or medical procedure on the portion of the patient's body inside the surgical environment enclosure, through at least a second port on the enclosure. The first port forms a seal around a surface of the patient's body upon or after insertion. In some embodiments, neither the entire body of the patient nor an entire body of any medical or surgical personnel fully enters the surgical environment enclosure during performance of the surgical or medical procedure.

An apparatus and method for aspirating, irrigating and / or cleansing wounds is provided. The apparatus and method include one or more of the following: simultaneous aspiration and irrigation of the wound, supplying of thermal energy to fluid circulated through the wound; supplying physiologically active agents to the wound; a biodegradable scaffold in contact with the wound bed; and application of stress or flow stress to the wound bed.

The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptide.

Vaccine formulations effective against Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA) are disclosed, as well as methods of using the vaccine formulations in the treatment, prevention and prophylaxis of Staphylococcus aureus infections in a subject.

A composition is provided for reducing bacterial growth in food products. The composition includes a wood extract containing polyphenols and may contain arabinogalactan. The composition suppresses or prevents the growth of E. coli and of Salmonella sp. The wood extract imparts little or no residual taste to the food product. However, it can readily be removed if desired by washing before use of the food. The composition may be essentially arabinogalactan-free to further reduce bacterial growth.

The present invention provides methods for removing a significant amount of bacteria (e.g., gram-negative bacteria and gram-positive bacteria, including bacteria with no or low affinity for heparan sulfate) from whole blood, serum or plasma using an adsorption media. The method can be used in extracorporeal treatments involving high volumetric flow rates and high linear flow rates.

A tooth cleaning and whitening method applies a light transmitting oxidizing gel to the teeth, after which a hand-held LED light source with a light transmitting lens and a cup forming a chamber having an open end is moved over the teeth so that the cup distributes the gel while the teeth are exposed to light transmitted through the lens. This not only ensures intimate contact of the teeth with the gel, but also maintains a more or less constant spacing between the light source and the tooth surfaces for optimum results. A sealant is then applied to the gel-coated teeth, after which a dental prophylaxis is performed by cleaning and scaling the teeth at the gum line, gingival margins, and crevicular spaces while avoiding excessive disruption of the sealant composition. This simultaneous cleaning and whitening procedure reduces patient time at the dentist compared to separate cleaning and whitening procedures.

Ventilator associated pneumonia (VAP) may be prevented in a patient, or its occurrence reduced in a population of patients, by using an anti-VAP device or an anti-VAP material such as an anti-VAP mouthpiece that absorbs secretions. By reducing the problem of bacterial-containing secretions that otherwise build up in the airway of, and elsewhere in, the intubated patient, VAP can be prevented from occurring in intubated patients, such as patients intubated with an endotracheal tube (ETT) or a nasogastric tube. Anti-VAP mouthpieces also are useable in non-intubated patients to maintain oral hygiene.

The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.

The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.

The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.

Provided herein, inter alia, is a method for sanitizing produce, by: treating the produce with a catholyte solution for a period of time sufficient to sanitize the produce; treating the produce with a solution containing chlorine for a period of time sufficient to further sanitize the produce; and treating the produce with a solution containing peroxyacetic acid for a period of time sufficient to further sanitize the produce, where treating with the catholyte solution, the solution containing chlorine, and the solution containing peroxyacetic acid yields at least an additional 1 log unit reduction in microbial load, as compared to produce treated with a single solution selected from the catholyte solution, the solution containing chlorine, and the solution containing peroxyacetic acid.

The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.

The invention discloses a static-pile composting method for treating cow dung harmlessly. The method comprises the three steps that S1, a microbial inoculant is prepared, in specific, four kinds of microorganisms including ABTNL-2 bacillus subtilis, bacillus licheniformis, bacillus cereus and lactobacillus are utilized to prepare the microbial complex inoculant for cow dung composting; S2, cow dung composting is built, in specific, the microbial inoculant is inoculated to the mixture after the cow dung and plant materials are mixed, composting is built up after the materials are mixed evenly,a ventilation and temperature monitoring device is arranged in the compost, and the surrounding part of the pile body is completely covered with stack to preserve the heat; and S3, compost managementis conducted, in specific, air is injected into the pile body so as to ensure rapid warming and decomposition of the compost, the pile body temperature is monitored, the product after composting serves as biological organic fertilizer. The method can achieve rapid, simple and convenient harmless treatment of cow dung of small-scale farmers, and particularly can rapidly and completely inactivate the enterohemorrhagic escherichia coli O157:H7 in the cow dung, and the composting product can serve as the biological organic fertilizer to achieve resource utilization.